Besides Covaxin, BharatBiotech has been actively engaged on creating one other vaccine, for which it has tied up with Washington UniversitySchool of Medicine in St Louis for the novel “chimp-adenovirus” (Chimpanzee adenovirus), a single dose intra nasal vaccine for Covid-19.
“BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021,” an e mail reply from town-primarily based vaccine maker instructed PTI.
Phase I human medical trials will probably be performed in India, Bharat Biotech added.
The firm is specializing in the intranasal vaccine as the present vaccines require two dose intramuscular injectionsKrishna Ella, Chairman, Bharat Biotech
The Phase-1 trials will probably be performed in Saint Louis University’s Vaccine and Treatment Evaluation Unit, the corporate sources mentioned including Bharat Biotech owns the rights to distribute the vaccine in all markets besides USA, Japan and Europe.
Krishna Ella, Chairman of Bharat Biotech had earlier mentioned the corporate is specializing in the intranasal vaccine as the present vaccines require two-dose intramuscular injections and a rustic like India wants 2.6 billion syringes and needles which can add up to air pollution.
An intranasal vaccine is not going to solely be easy to administer however scale back the use of medical consumables akin to needles, syringes, and so forth., considerably impacting the general value of a vaccination drive, he had mentioned.
“One drop of vaccine in each of the nostrils is sufficient,” he had mentioned.
An intranasal vaccine is not going to solely be easy to administer however scale back the use of medical consumables akin to needles, syringesElla
According to him, protecting a number of points in thoughts BharatBiotechtied up withWashingtonUniversitySchool of Medicine for the only-dose intra nasal vaccine for Covid-19. He had mentioned Bharat Biotech envisions that it could scale this vaccine to one billion doses, translating into equal quantity of people being vaccinated receiving a single-dose routine.
BharatBiotech, upon acquiring required regulatory approval, will pursue additional phases of medical trials in India and undertake massive scale manufacture of the vaccine at its GMP (good manufacturing apply) facility situated in Genome Valley, right here, the corporate had earlier mentioned.
The intranasal vaccine candidate has proven unprecedented ranges of safety in mice research and the know-how and information having been already revealed in the distinguished scientific journal ‘Cell’ and in an editorial in ‘Nature’, the corporate had mentioned.
Bharat Biotech has efficiently accomplished enrollment of 25,800 volunteers for the Phase-3 trials of its Covid-19 vaccine Covaxin.
(This story has not been edited by Newslivenation employees and is auto-generated from a syndicated feed.)